The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.
April 22nd 2024
SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma.
Dr. Andtbacka Discusses the Role of T-VEC in Melanoma
February 24th 2018Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the role of talimogene laherparapvec (T-VEC; Imlygic) in the treatment of patients with melanoma.
Triplet Therapy May Be on the Horizon for BRAF-Mutant Melanoma
The past decade of drug discovery has brought a dramatic expansion in the number of new therapies to treat patients with advanced or metastatic melanoma in 2 modalities: checkpoint blockade immunotherapies and molecularly targeted drugs.
Analysis Explores Continuing Anti-PD-1 Therapy Past Progression in Melanoma
Investigators with the FDA’s Center for Drug Evaluation and Research and Oncology Center of Excellence conducted a pooled analysis of all trial reports and data marketing applications for the use of anti–PD-1 antibodies alone or in combination to treat patients with unresectable or metastatic melanoma.
Bristol-Myers Squibb Gains NKTR-214 Access in Nektar Collaboration
Bristol-Myers Squibb and Nektar Therapeutics have announced plans to jointly develop and market combinations of the CD122-biased cytokine NKTR-214 with nivolumab (Opdivo) or nivolumab plus ipilimumab (Yervoy) across for 20 indications in 9 tumor types.